Clinical Trials Sponsored by Affymax

Total 17 results

Affymax

Completed

Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Bulgaria, Romania, United Kingdom
Affymax

Terminated

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Bulgaria, Romania, Poland, United Kingdom
Affymax

Terminated

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Affymax

Completed

Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom, Poland
Affymax

Terminated

Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom
Affymax

Completed

Peginesatide for Anemia in Chronic Hemodialysis Patients

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Affymax

Completed

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Cancer | Chemotherapy Induced Anemia

Czech Republic, Poland, United Kingdom
Affymax

Completed

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Cancer | Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, Romania, United Kingdom, Italy, Poland, France, Germany, Spain
Affymax
Takeda

Completed

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis (PEARL 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, United Kingdom, Czech Republic, Germany, Hungary, Italy, Poland, Puerto Rico, Romania
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Russian Federation
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis (PEARL 1)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Puerto Rico
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 1)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Takeda
Affymax

Completed

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (DIAMOND)

Anemia | Chronic Kidney Disease

United States
Takeda
Affymax

Completed

Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.

Anemia

United States, New Zealand, Australia, Italy, United Kingdom
Takeda
Affymax

Completed

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Anemia

United States
Takeda
Affymax

Terminated

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Anemia

United States

3

Subscribe